The NKG2A blocking antibody monalizumab is currently in a phase III clinical trial in combination with durvalumab (anti-PD-L1) for the treatment of patients with nonsmall-cell lung cancer (NCT05221840). The gene discussed is KLRC1; the disease is lung cancer.